Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Montplaisir, Jacques ^a   Petit, Dominique ^a   Quinn, Marie Josée ^a   Ouakki, Manale ^b   Deceuninck, Geneviève ^c   Desautels, Alex ^a   Mignot, Emmanuel ^d   De Wals, Philippe ^e  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; ALPHA TOCOPHEROL; ASO3B ADJUVANT; DRUG COMBINATION; IMMUNOLOGICAL ADJUVANT; POLYSORBATE; SQUALENE;

2009 H1N1 INFLUENZA; ADULT; ARTICLE; CANADA; CATAPLEXY; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; HUMAN; INFLUENZA VACCINATION; MALE; NARCOLEPSY; PANDEMIC INFLUENZA; PATIENT IDENTIFICATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; ADOLESCENT; CASE CONTROL STUDY; CHILD; DRUG COMBINATION; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; MIDDLE AGED; VACCINATION; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALPHA-TOCOPHEROL; CASE-CONTROL STUDIES; CHILD; DRUG COMBINATIONS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NARCOLEPSY; POLYSORBATES; QUEBEC; RETROSPECTIVE STUDIES; SQUALENE; VACCINATION; YOUNG ADULT;

EID: 84907494540     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108489     Document Type: Article

References (38)

1. Dauvilliers Y, Arnulf I, Mignot E (2007) Narcolepsy with cataplexy. Lancet 369(9560): 499-511
2. Burgess CR, Scammell TE (2012) Narcolepsy: neural mechanisms of sleepiness and cataplexy. J Neurosci 32(36): 12305-11
3. Longstreth WT Jr, Koepsell TD, Ton TG, Hendrickson AF, van Belle G (2007) The epidemiology of narcolepsy. Sleep 30(1): 13-26
4. Mignot E, Tafti M, Dement WC, Grumet FC (1995) Narcolepsy and immunity. Adv Neuroimmunol 5(1): 23-37
5. Singh AK, Mahlios J, Mignot E (2013) Genetic association, seasonal infections and autoimmune basis of narcolepsy. J Autoimmun 43: 26-31
6. Orellana C, Villemin E, Tafti M, Carlander B, Besset A, et al. (1994) Life events in the year preceding the onset of narcolepsy. Sleep 17(Suppl8): S50-3
7. Lankford DA, Wellman JJ, O'Hara C (1994) Posttraumatic narcolepsy in mild to moderate closed head injury. Sleep 17(Suppl8): S25-8
8. Picchioni D, Hope CR, Harsh JR (2007) A case-control study of the environmental risk factors for narcolepsy. Neuroepidemiology 29(3-4): 185-192
9. Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, et al. (2012) AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 7(3): e33536. doi:10.1371/journal.pone.0033536. Accessed 2014 Sept 1
10. Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, Hublin C, Linna M, et al. (2012) Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One 7(3): e33723
11. National Narcolepsy Study Steering Committee (2012) Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010. Dublin, Ireland: Department of Health and Children. Available: http:// www.dohc.ie/publications/pdf/Final-Report-of-National-Narcolepsy-Study- Steering-Committee.pdf?direct=1. Accessed 2014 Sept 1
12. ECDC Technical Report (2012) Narcolepsy in association with pandemic influenza vaccination. Stockholm: European Centre for Disease Prevention and Control. Available: http://www.ecdc.europa.eu/en/publications/Publications/ Vaesco%20in%20brief%20final.pdf. Accessed 2014 Sept 1
13. Miller E, Andrews N, Stellitano L, Stowe J, Winstone AM, et al. (2013) Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 346: f794. doi:10.1136/bmj.f794
14. Dauvilliers Y, Montplaisir J, Cochen V, Desautels A, Einen M, et al. (2010) Post- H1N1 narcolepsy-cataplexy. Sleep 33(11): 1428-30
15. Ministère de la Santé et des Services sociaux du Québec (MSSS) (2011) Bilan de la direction générale de la santé publique de la vaccination contre la grippe pandémique A(H1N1) 2009. Du 22 octobre au 18 décembre 2009. Québec: Direction de la protection de la santé publique, Ministère de la Santé et des Services sociaux du Québec, 2011. Available: http://publications.msss.gouv.qc.ca/acrobat/f/documentation/2011/11-220-02.pdf. Accessed 2014 Sept 1
16. Poli F, Overeem S, Lammers GJ, Plazzi G, Lecendreux M, et al. (2013) Narcolepsy as an adverse event following immunization: Case definition and guidelines for data collection, analysis and presentation. Vaccine 31(6): 994-1007
17. De Wals P, Deceuninck G, Toth E, Boulianne N, Brunet D, et al. (2012) Risk of Guillain-Barré Syndrome following H1N1 influenza vaccination in Quebec. JAMA 308(2): 175-81
18. Whitaker HJ, Farrington CP, Spiessens B, Musonda P (2006) Tutorial in biostatistics: The self-controlled case series method. Stat Med 25(10): 1768-97
19. Comstock GW (1994) Evaluating vaccination effectiveness and vaccine efficacy by means of case-control studies. Epidemiol Rev 16(1): 77-89
20. Silber MH, Krahn LE, Olson EJ, Pankratz VS (2002) The epidemiology of narcolepsy in Olmsted County, Minnesota: A population-based study. Sleep 25(2): 197-202
21. Wijnans L, Lecomte C, de Vries C, Weibel D, Sammon C, et al. (2013) The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1) pdm09 pandemic and vaccination campaigns. Vaccine 31(8): 1246-54
22. Morrish E, King MA, Smith IE, Shneerson JM (2004) Factors associated with a delay in the diagnosis of narcolepsy. Sleep Medicine 5(1): 37-41
23. Mignot E, Lin X, Kalil J, George C, Singh S, et al. (1992) DQB1-0602 (DQw1) is not present in most nonDR2 Caucasian narcoleptics. Sleep 15(5): 415-22
24. Poirier G, Montplaisir J, Décary F, Momège D, Lebrun A (1986) HLA antigens in narcolepsy and idiopathic central nervous system hypersomnolence. Sleep 9(1 Pt 2): 153-8
25. Mignot E, Hayduk R, Black J, Grumet FC, Guilleminault C (1997) HLA DQB1.∗0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 20(11): 1012-20
26. Mignot E, Kimura A, Lattermann A, Lin X, Yasunaga S, et al. (1997) Extensive HLA class II studies in 58 non-DRB1.∗15 (DR2) narcoleptic patients with cataplexy. Tissue Antigens 49(4): 329-41
27. Institut national de santé publique du Québec (INSPQ) (2010) Bilan épidémiologique de la pandémie d'influenza A(H1N1). Province de Québec- 2009. Québec: Direction des risques biologiques et de la santé au travail, Institut national de santé publique du Québec, 2010. Available: http://www.inspq.qc. ca/pdf/publications/1212-BilanAH1N12009.pdf. Accessed 2014 Sept 1
28. Han F, Lin L, Li J, Dong XS, Mignot E (2013) Decreased incidence of childhood narcolepsy 2 years after the 2009 H1N1 winter flu pandemic. Ann Neurol 73(4): 560. doi:10.1002/ana.23799
29. Han F, Lin L, Warby SC, Faraco J, Li J, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 70(3): 410-7
30. Choe YJ, Bae GR, Lee DH (2012) No association between influenza A (H1N1) pdm09 vaccination and narcolepsy in South Korea: An ecological study. Vaccine 30(52): 7439-42
31. Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson JA, et al. (2011) Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 342: c7297. doi:10.1136/bmj.c7297
32. Van Buynder PG, Dhaliwal JK, Van Buynder JL, Couturier C, Minville- Leblanc M, et al. (2010) Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. Influenza Other Respir Viruses 4(4): 171-8
33. Melèn K, Partinen M, Tynell J, Sillanpää M, Himanen SL, et al. (2013) No serological evidence of influenza A H1N1pdm09 virus infection as a contributing factor in childhood narcolepsy after Pandemrix vaccination campaign in Finland. PLoS ONE 8(8): e68402. doi:10.1371/journal.pone.0068402.
34. Heier MS, Gautvik KM, Wannag E, Bronder KH, Midtlyng E, et al. (2013) Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Medicine 14: 867-71
35. Medical Product Agency (2011) Occurrence of narcolepsy with cataplexy among children and adolescents in relation to the H1N1 pandemic and Pandemrix vaccinations - Results of a case inventory study by the MPA in Sweden during 2009-2010. Stockholm, Sweden: Läkemedelsverket. Available: http://www. lakemedelsverket.se/upload/nyheter/2011/Fallinventeringsrapport- pandermrix-110630.pdf. Accessed 2014 Sept 1
36. European Medicine Agency (2013) Pandemrix: EPAR-Product Information Annex I: Summary of product characteristics. London (UK): European Medicine Agency. Available: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000832/ WC500038121.pdf. Accessed 2014 Sept 1
37. GlaxoSmithKline Inc (2009) Product Information Leaflet Arepanrix H1N1 AS03-Adjuvanted H1N1 Pandemic Influenza Vaccine - Version 4 approved 20 April 2010. Ottawa: Health Canada, 2010. Available: http://www.hc-sc.gc.ca/ dhp-mps/alt-formats/pdf/prodpharma/legislation/interimordersarretesurgence/ prodinfo-vaccin-eng.pdf. Accessed 2014 Sept 1
38. Ahmed SS, Schur PH, MacDonald NE, Steinman L (2014) Narcolepsy 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: What is known and unknown about the neurological disorder, the role of autoimmunity, and vaccine adjuvants. J Autoimmunity 50: 1-11.